A new meta-analysis of more than 6000 studies shows that oral contraceptives significantly reduce the risk of ovarian cancer. The risk reduction increases proportionally with duration of use.
See the abstract here
Related Topics
Advocate’s Corner: October 2024
We are weeks away from election day and there is still work to be done! With Congress in recess until after the election, there is a short window of time … Continued
OCRA-Funded Research Makes Inroads Toward Effective CAR T-Cell Therapies
A research team, led by Dr. Ugo Cavallaro and supported by OCRA’s 2019 Collaborative Research Development Grant, made progress toward improving immunotherapies for ovarian cancer. Dr. Frances R. Balkwill, a … Continued
OCRA Co-authors Collaborative Study Identifying & Addressing Caregiver Needs
Leaders in the patient advocacy space came together for a wide-ranging study on the often-overlooked challenges faced by caregivers of cancer patients, with Tracy Moore, LCSW, who serves as Ovarian … Continued